

INDEX

Contents	Page No.
List of Figures	xi
List of Tables	xvi
Abbreviations and Symbols	xvii
Preface	xxi
CHAPTER 1. INTRODUCTION	1
1.1 Alzheimer's disease	1
1.2 Pathophysiological mechanisms involved in AD	2
1.2.1 Cholinergic hypothesis	2
1.2.2 A β hypothesis	4
1.2.3 Excitotoxic hypothesis	6
1.2.4 Oxidative stress hypothesis	6
1.2.5 Tau hypothesis	7
1.2.6 APO ϵ 4 hypothesis	9
1.2.7 CREB signaling pathways	10
1.3 Available neurotherapeutics for the treatment of AD	11
1.4 Novel therapeutic strategies for the development and discovery of compounds for the treatment of AD	11
1.4.1 Multitarget approach	12
1.4.2 Computer-aided drug design approach	13
1.4.3 Molecular hybridization	14
1.5 Design hypothesis in the present study	14
CHAPTER 2. REVIEW OF LITERATURE	16
2.1. <i>N</i> -Benzylpiperidines: Development as multitargeted ligands in AD	16
2.2. 1,3,4-Oxadiazoles: Development as multitargeted ligands in AD	26
CHAPTER 3. RATIONALE, OBJECTIVES AND PLAN OF WORK	31
3.1. Rationale and objectives	31
3.1.1 Designing of Part-I (Series I) ligands	32
3.1.2 Designing of Part-II (Series II–V) ligands	33
3.2. Plan of work	35
CHAPTER 4. EXPERIMENTAL	37
4.1 Computational studies	37
4.1.1 Pharmacophore modeling	37
4.1.2 Virtual screening and docking-post processing (DPP)	37
4.1.3 MM-GBSA	38
4.1.4 Molecular docking study	38
4.1.5 Molecular dynamics simulations study	38

Contents	Page No.
4.2 Synthesis	39
4.2.1 Chemicals and reagents	39
4.2.2 Series I: <i>N</i> -Benzylpiperidine analogs with substituted phenyl methanimines/ methanamines	39
4.2.2.1 General procedure for synthesis of compounds (S_I3a–o)	39
4.2.2.2 General procedure for synthesis of compounds (S_I4a–o)	40
4.2.3 Series II: <i>N</i> -Benzylpiperidine and substituted benzylidenehydrazine-1-carboxamides and Series III: 5-Phenyl-1,3,4-oxadiazoles tethered with an —NH linker	40
4.2.3.1 General procedure for synthesis of compounds (S_{II}7)	41
4.2.3.2 General procedure for synthesis of compounds (S_{II}8)	41
4.2.3.3 General procedure for synthesis of compounds Series II (S_{II}9a–h)	41
4.2.3.4 General procedure for synthesis of compounds Series III (S_{III}10a–c)	42
4.2.3.5 General procedure for synthesis of compounds Series III (S_{III}10d–h)	42
4.2.4 Series IV: <i>N</i> -Benzylpiperidine and substituted 5-phenyl-1,3,4-oxadiazoles tethered with the —NHCH ₂ linker	42
4.2.4.1 General procedure for synthesis of compounds (S_{IV}12–h)	43
4.2.4.2 General procedure for synthesis of compounds (S_{IV}13–h)	43
4.2.4.3 General procedure for synthesis of compounds Series IV (S_{IV}14–h)	43
4.2.5 Series V: <i>N</i> -Benzylpiperidine and substituted 5-phenyl-1,3,4-oxadiazoles tethered without linker	44
4.2.5.1 General procedure for synthesis of compounds (S_V16a–h and S_V17a–h)	44
4.3 Characterization of the synthesized compounds	45
4.3.1 Melting point	45
4.3.2 TLC (R _f value)	45
4.3.3 FT-IR	45
4.3.4 ¹ H NMR and ¹³ C NMR	45
4.3.5 Mass spectra	46
4.3.6 Determination of percentage purity by HPLC	46
4.4 Biological Evaluation	46
4.4.1 <i>In vitro</i> studies	46
4.4.1.1 Cholinesterase inhibition by Ellman assay	46
4.4.1.2 Enzyme kinetics study	47
4.4.1.3 BACE-1 inhibition assay	47

Contents	Page No.
4.4.1.4 Propidium iodide displacement assay	48
4.4.1.5 Parallel artificial membrane permeation assay (PAMPA)	49
4.4.1.6 A β aggregation (self- and AChE-induced) inhibition by thioflavin T assay	49
4.4.1.7 AFM study	50
4.4.1.8 Neurotoxic liabilities against SH-SY5Y cell lines by MTT assay	51
4.4.2 <i>In vivo</i> and <i>ex vivo</i> studies	51
4.4.2.1 Animals	51
4.4.2.2 Acute oral toxicity study	51
4.4.2.3 Scopolamine-induced amnesia model: Y-maze test	52
4.4.2.4 <i>Ex vivo</i> studies: AChE estimation and antioxidant activity	53
4.4.2.5 A β -induced AD phenotypic model: Morris water maze test	54
4.4.2.6 Western-blot analysis	55
4.4.2.7 Immunohistochemical analysis	56
4.4.3 Pharmacokinetic studies	57
CHAPTER 5. RESULTS AND DISCUSSION	58
5.1 PART-I: SERIES I	58
5.1.1 Computational studies and designing considerations	58
5.1.1.1 Pharmacophore modeling	58
5.1.1.2 Virtual screening and docking-post processing (DPP)	59
5.1.1.3 MM-GBSA	60
5.1.1.4 Molecular docking study	61
5.1.1.5 Molecular dynamics simulations study	63
5.1.2 Chemistry	67
5.1.2.1 Synthesis of Series I: <i>N</i> -Benzylpiperidine with substituted phenyl methanimines/methanamines	67
5.1.2.2 Characterization of the synthesized compounds (Series I)	68
5.1.3 Biological evaluation	80
5.1.3.1 <i>In vitro</i> studies	80
5.1.3.2 <i>In vivo</i> and <i>ex vivo</i> studies	80
5.1.3.3 Pharmacokinetic studies	89
5.2 PART-II: SERIES II–V	93
5.2.1 Chemistry	94
5.2.1.1 Synthesis of Series II (S_{II}9a–h) and III (S_{III}10a–h): <i>N</i> -Benzylpiperidine with substituted benzylidenehydrazine-1-carboxamides and substituted 5-phenyl-1,3,4-oxadiazoles tethered with —NH linker	94

Contents	Page No.
5.2.1.2 Characterization of the synthesized compounds (Series II and III)	95
5.2.1.3 Synthesis of Series IV (S_{IV}14a–h): <i>N</i> -Benzylpiperidine and substituted 5-phenyl-1,3,4-oxadiazoles tethered with —NHCH ₂ linker	103
5.2.1.4 Characterization of the synthesized compounds (Series IV)	104
5.2.1.5 Synthesis of Series V (S_V17a–h): <i>N</i> -Benzylpiperidine and substituted 5-phenyl-1,3,4-oxadiazoles tethered without linker	111
5.2.1.6 Characterization of the synthesized compounds (Series V)	112
5.2.2 Biological evaluation	115
5.2.2.1 <i>In vitro</i> studies	115
5.2.2.2 <i>In vivo</i> and <i>ex vivo</i> studies	126
5.2.2.3 Pharmacokinetic studies	132
5.2.3 Computational studies	133
5.2.3.1 Molecular docking study	133
5.2.3.2 Molecular dynamics simulations study	135
CHAPTER 6. SUMMARY AND CONCLUSION	140
6.1. Scope and future directions	143
CHAPTER 7. REFERENCES	145
CHAPTER 8. APPENDIX	161
8.1. ¹ H and ¹³ C spectra of representative synthesized compounds	161
8.2. Mass spectra of representative synthesized compounds	188
8.3. HPLC chromatograms of representative synthesized compounds	190
LIST OF PUBLICATIONS	197